Country | Total CTAs† | CTAs by type of sponsor | CTAs by type of trial phase | ||||
Commercially sponsored CTAs | Non-commercially sponsored CTAs | Phase I CTAs | Phase II CTAs | Phase III CTAs | Phase IV CTAs | ||
AAGRs in the period 2007–2015 (%) | |||||||
All countries | −1.4 | −1.5 | −1.1 | −2.8* | −2.2* | −0.9 | −4.3* |
Germany | −3.7* | −3.2* | −6.0** | −5.9* | −3.3* | −1.8* | −5.7* |
Italy‡ | −3.9* | −1.6 | −8.5* | 9.6* | −6.1* | −5.0* | −9.5* |
Spain | 2.3* | 1.9 | 3.5 | 5.9** | 1.2 | 3.5* | −3.2* |
France | 0.9 | 0.9 | 0.9 | – | – | – | – |
The UK§ | −1.5 | −1.2 | −2.5 | −5.1** | 2.5 | −8.6* | |
Belgium | 0.4 | −0.9 | 6.6* | −0.9 | −0.8 | 1.5 | 2.6 |
The Netherlands¶ | −1.1 | −1.2 | −1.1 | −0.6 | 1.8 | −1.4 | −2.9 |
Austria | −2.8* | −3.7 | −0.5 | −1.6 | −5.4* | −1.7 | −4.0 |
Denmark | 2.1 | −1.8 | 9.5** | 194 | 4.4 | 4.0 | 4.3 |
Sweden | −5.6** | −7.3** | −0.2 | −17** | −3.9 | −3.5* | −4.5 |
AAGRs in the period 2007–2011 (%) | |||||||
All countries | −3.9* | −4.7* | −1.5 | −2.4 | −1.1 | −2.0 | −6.4 |
Germany | −2.4 | −2.2 | −3.3* | −3.7 | −1.8 | −2.1 | −3.7 |
Italy‡ | −5.6 | −4.4 | −7.6 | 14.4 | −5.4 | −7.6 | −6.4 |
Spain | 2.3 | −2.1 | 18.6* | 5.5 | 3.0 | 1.0 | 0.7 |
France | −6.0* | −6.0* | −6.0* | – | – | – | – |
The UK§ | −6.3* | −6.5* | −5.7 | −4.4 | −3.8 | −13* | |
Belgium | −3.9 | −4.7 | 0.6 | −3.8 | −5.1 | −1.5 | −9.1 |
The Netherlands¶ | −4.2 | −6.1 | −1.2 | −4.4 | −1.9 | −4.3 | −7.4 |
Austria | −2.0 | −1.9 | −2.4 | 9.4 | −0.5 | −1.2 | −9.8 |
Denmark | −1.8 | −8.7* | 14.1* | – | – | – | – |
Sweden | −7.9* | −11* | 1.7 | −13** | −4.3 | −8.1* | −6.4 |
AAGRs in the period 2012–2015 (%) | |||||||
All countries | 2.6 | 3.1 | 1.1 | −0.2 | −5.6 | −2.9 | 0.8 |
Germany | −0.2 | 0.0 | −1.3 | −3.4 | −2.2 | 2.5 | 7.6 |
Italy‡ | −1.7 | −1.7 | −1.8 | 17.2 | −9.3 | −9.1 | −24 |
Spain | 2.3 | 4.4 | −4.3 | 3.9 | −1.8 | 5.1 | 0.4 |
France | 7.3 | 7.4 | 7.3 | – | – | – | – |
The UK§ | 3.9 | 4.5 | 1.7 | −1.4 | 5.2* | 5.0 | |
Belgium | 5.0 | 4.3 | 7.7 | 2.7 | 0.2 | 7.3 | 14.2 |
The Netherlands¶ | 2.3 | 6.7 | −3.7 | 4.6 | 16.2 | 0.5 | 4.8 |
Austria | −1.0 | 1.6 | −6.9 | 2.9 | −7.5 | 0.4 | −1.8 |
Denmark | 7.1 | 6.7 | 7.7 | 14.5 | 5.7 | 5.1 | 6.3 |
Sweden | 0.0 | −2.6 | 7.3* | 12.0 | −6.2 | −3.5* | 5.4 |
+Data from Italy, France and Spain refer to the numbers of authorised clinical trials and not clinical trial applications.
†Phases can overlap. Thus, the summarised number of clinical trial applications for all trial phases is not necessarily equal to the total number of clinical trial applications registered.
‡AAGR in the period 2011–2015 for Italy only includes data from 2011 to 2014.
§In the UK, phase II and III clinical trials are registered together and could therefore not be separated.
¶Some clinical trials are not specified by the sponsor in regards to the trial phase. The national competent authorities of Italy and the Netherlands have registered these as not specified. These trials are not included in this table.
*Indicates p<0.05.
**Indicates p<0.001.